重要内容提示： 浙江康恩贝制药股份有限公司（以下简称"公司"）董事会于 2025 年 10 月 17 日收到 公司副总裁沈旗先生递交的书面辞职报告，因工作调整原因，沈旗先生向公司董事会申请 辞去副总裁职务。沈旗先生辞去副总裁职务后，将不再担任公司投资总监职务，仍担任公 司控股子公司浙江中医药大学中药饮片有限公司董事长职务。 证券代码：600572 证券简称：康恩贝 公告编号：2025-050 浙江康恩贝制药股份有限公司 关于高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （二）离任对公司的影响 根据《中华人民共和国公司法》《公司章程》等有关规定，沈旗先生的辞职 自公司董事会收到辞职报告时生效。沈旗先生的离任不会影响公司的正常运作及 经营管理。截至本公告披露日，沈旗先生未持有公司股份。 沈旗先生在任职期间恪尽职守，勤勉尽责，公司及董事会对沈旗先生在任职 期间所作的贡献表示衷心感谢！ 特此公告。 浙江康恩贝制药股份有限公司董事会 2025 年 10 月 18 日 一、董事/高级管理人员离任情况 （一）提前离 ...

Core Viewpoint - The company announced the resignation of Vice President Shen Qi due to work adjustment reasons, effective immediately upon receipt of the resignation letter by the board [1] Group 1 - Shen Qi will no longer serve as Vice President and will also step down from the position of Investment Director [1] - Despite resigning from these roles, Shen Qi will continue to hold the position of Chairman at the company's subsidiary, Zhejiang University of Traditional Chinese Medicine Herbal Pieces Co., Ltd. [1]

Core Viewpoint - 康恩贝 is actively seeking acquisition opportunities in line with its strategic focus on traditional Chinese medicine and health, considering various factors for potential targets [1] Group 1: Acquisition Strategy - The company evaluates acquisition targets based on strategic alignment, revenue and profit size, growth potential, and compatibility with existing treatment areas and marketing channels [1] - The acquisition efforts are progressing as planned and will be disclosed in future updates [1]

Group 1 - The company does not currently offer special discount activities for shareholders [2] - The company's health consumer products, such as protein powder, vitamins, and probiotics, can be purchased through official flagship stores on platforms like Tmall, JD.com, Pinduoduo, and Douyin [2]

Core Viewpoint - The announcement details the stock option incentive plan of Zhejiang Kangnbei Pharmaceutical Co., Ltd. for the third quarter of 2025, highlighting the number of shares exercised and the related procedures [1][2]. Summary by Sections Stock Option Exercise Details - In the third quarter of 2025, a total of 3.604973 million shares were exercised under the 2022 stock option incentive plan [2]. - The exercised shares will be tradable on the second trading day after the exercise date [2]. Decision-Making Process and Information Disclosure - The plan was approved by the board and supervisory committee in September 2022, with detailed disclosures made on the Shanghai Stock Exchange and other designated media [2][3]. - The plan included the granting of 70 million stock options to eligible participants, with the first grant completed in November 2022 [3]. Adjustments to Stock Option Terms - The exercise price of the stock options was adjusted from 4.13 CNY to 3.98 CNY in June 2023, and further adjustments were made in July 2024 and June 2025 [3][4][5]. - The number of stock options granted was also adjusted, with 752.5 thousand reserved options granted in October 2023 [3][4]. Shareholder and Management Participation - A total of 97 participants exercised their options in the third quarter of 2025 [7]. - The shares resulting from the exercise are subject to a six-month lock-up period for directors and senior management [10]. Financial Impact and Fund Utilization - The exercise of options raised approximately 13.086052 million CNY, contributing to a total of 69.266768 million CNY raised to date, which will be used to supplement the company's working capital [12]. - The impact of the exercised shares on the company's financial status and operational results is not considered significant [12].

证券代码：600572 证券简称：康恩贝 公告编号：临2025-049 浙江康恩贝制药股份有限公司 关于2025年第三季度股票期权激励计划 自主行权结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要提示内容： 1、本次行权股票数量：2025年第三季度，浙江康恩贝制药股份有限公司（以下简称"公司" "本公司"）2022年股票期权激励计划（以下简称"本次激励计划"）首次授予股票期权激励对 象行权且完成股份过户登记的股票数量合计为360.4973万股。 2、本次行权股票上市流通时间：采用自主行权方式行权，激励对象（除公司董事、高级管 理人员外）行权所得股票于行权日（T 日）后的第二个交易日（T+2）日可上市交易。 2025年第三季度，公司本次激励计划激励对象行权且完成股份过户登记的股票 数量合计为360.4973万股。有关情况公告如下： 一、本次激励计划已履行的决策程序及相关信息披露 （一）2022年9月15日，公司十届董事会第二十二次（临时）会议和十届监事会 第十三次（临时）会议分别审议通过了《关于<浙江康恩 ...

Group 1: 康恩贝 - The company aims to acquire potential large products that align with its strategic direction, with ongoing discussions for relevant targets [1] - The acquisition strategy considers strategic fit, revenue and profit potential, growth opportunities, and compatibility with existing treatment areas and marketing channels [1] - The company has strengthened its business development (BD) system, with a recently approved modified new drug for throat relief as an example of a more efficient and asset-light "acquisition" [1] Group 2: 甘李药业 - The company signed a technology transfer and supply agreement with Fundação Oswaldo Cruz-Bio-Manguinhos and BIOMM for the production of insulin in Brazil [2] - The total amount of the supply framework agreement is expected to be no less than 3 billion RMB, with actual order amounts to be determined [2] - The agreement includes technology transfer for insulin and commitments for future procurement by FZ over the next 10 years [2] Group 3: 天目药业 - The company is focused on the inheritance and innovation of traditional Chinese medicine, accelerating the resumption of production for quality products like pearl eye drops [3] - It has made significant progress in drug re-registration, with 53 drugs receiving approval notifications since the beginning of 2025, surpassing the total for 2024 [3] - The company is leveraging existing product advantages to launch new products to meet diverse consumer needs [3] Group 4: 济民健康 - The company plans to enhance cooperation and increase investment in innovative drug research, aiming to establish Boao International Hospital as a high-level clinical research center [4] - The company holds a 51% stake in Boao International Hospital, with various stakeholders involved in the remaining shares [4] Group 5: 恒瑞医药 - The company signed a licensing agreement with Glenmark Specialty for its innovative drug SHR-A1811, with potential earnings exceeding 1.1 billion USD [5][6] - The drug targets HER2 and is designed to induce apoptosis in tumor cells, enhancing anti-tumor efficacy [5] - Glenmark Specialty will pay an upfront fee of 18 million USD and is eligible for milestone payments based on registration and sales [6] Group 6: 华熙生物 - The company’s strategic investment in Sanofi Pharmaceuticals is aimed at enhancing its presence in the biopharmaceutical sector [7] - The investment allows for collaboration in the development of small nucleic acid innovative drugs, creating synergies across its main business areas [7] - The company is exploring the role of hyaluronic acid and other substances in advanced medical research and applications [7]

Core Insights - The company is expanding the indications for its major products, including "Zhixinxuan" and "Jindi," to enhance market competitiveness and meet diverse patient needs [1] - The company's revenue and net profit for the first half of 2025 have decreased year-on-year, primarily due to a decline in sales of respiratory and anti-infection products, coupled with a shift in revenue mix towards lower-margin health consumer products [1] - The company is actively seeking acquisition opportunities to align with its strategic focus on traditional Chinese medicine and health, evaluating potential targets based on strategic fit, revenue potential, and compatibility with existing product lines [2] Financial Performance - The company reported a year-on-year decline in both operating revenue and net profit for the first half of 2025 [1] - The decrease in net profit was more significant than the decline in operating revenue due to a higher proportion of lower-margin products in the revenue mix [1] Acquisition Strategy - The company is enhancing its business development (BD) system to identify and acquire potential high-value products that align with its strategic direction [2] - Recent approvals for new products, such as the throat lozenge, are part of a strategy to enrich the product pipeline in the cold and throat category [2] - Ongoing discussions for potential acquisition targets are in progress, although previous projects have not yet materialized due to various reasons [2]

Core Viewpoint - The recent suspension of procurement qualifications for acetylcysteine effervescent tablets produced by Zhejiang Jinhua Kang En Bei Pharmaceutical Co., Ltd. due to non-compliance with regulations poses significant challenges for the company, particularly during its critical transformation phase into "Traditional Chinese Medicine (TCM) Health" [2][3][9]. Group 1: Company Performance and Financial Impact - In 2022, the sales revenue of acetylcysteine effervescent tablets was nearly 300 million yuan, with a year-on-year growth of over 16% in 2023, estimated to reach approximately 350 million yuan, accounting for over 5% of total revenue [2]. - The company's revenue for the first half of 2025 was 3.358 billion yuan, with a net profit of 354 million yuan, both showing a decline, continuing the downward trend from 2024 [5]. - The core chemical drug business saw a revenue drop of 11.22% in the first half of 2025, primarily due to the failure to win bids in the national centralized procurement [5][10]. Group 2: Quality Control and Regulatory Issues - The National Medical Products Administration announced the suspension of sales and recall measures for acetylcysteine effervescent tablets due to non-compliance with specifications, which directly impacts the business line reliant on this product [3][8]. - The quality issues have exposed vulnerabilities in the company's quality control processes, raising concerns about its strategic execution capabilities [2][11]. Group 3: Strategic Transformation Challenges - The company is undergoing a critical transformation into "TCM Health," facing difficulties as traditional Chinese medicine revenues are projected to decline in 2024, and the chemical drug sector has suffered quality setbacks [2][9]. - The company's recent restructuring efforts, including the introduction of a state-owned entity as a controlling shareholder, have not alleviated the pressures from price reductions in centralized procurement and rising raw material costs [9][10]. - Despite increasing R&D investments, the company's R&D intensity has decreased, indicating challenges in maintaining competitive innovation levels [10]. Group 4: Market Position and Brand Value - As of September 16, 2025, the company's market value was 11.384 billion yuan, ranking 23rd in the TCM sector, reflecting a significant decline in industry standing [8]. - The recent quality crisis is expected to have long-term implications for brand value and consumer trust, particularly in the respiratory medication sector [11].

Core Viewpoint - The company, Zhejiang Conba Pharmaceutical Co., Ltd., is holding a half-year performance briefing on September 23, 2025, to enhance communication with investors and address their concerns regarding the company's performance and financial indicators [2][3][4]. Group 1: Meeting Details - The meeting is scheduled for September 23, 2025, from 2:00 PM to 3:00 PM [4]. - It will take place at the Shanghai Stock Exchange Roadshow Center, accessible via the website https://roadshow.sseinfo.com/ [4]. - The format of the meeting will be an online text interaction, allowing for real-time communication with investors [3][4]. Group 2: Participation Information - Investors can participate in the meeting by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date [5]. - Questions can be submitted from September 16 to September 22, 2025, through the "Pre-Question Collection" section on the website or via the company's email [5][6]. - The company will address commonly asked questions during the performance briefing [5]. Group 3: Company Representatives - Key personnel attending the briefing include Chairman Jiang Yi, Vice President and CFO Chen Ming, Secretary of the Board Jin Zucheng, and Independent Director Qiu Baoyin [4].